Profusa

San Francisco, United States Founded: 2009 • Age: 17 yrs
Biochemical sensors are developed for real-time chronic disease monitoring.
Request Access

About Profusa

Profusa is a company based in San Francisco (United States) founded in 2009. It operates as a HealthTech, and Product-as-a-Service. Profusa has raised $64.92 million across 19 funding rounds from investors including Nasdaq, NIH and HHS. Profusa offers products and services including Lumee Oxygen Platform and Glucose Biosensors. Profusa operates in a competitive market with competitors including Theranica, Mainstay Medical, Sooma Oy, SPR Therapeutics and ZetrOZ, among others.

  • Headquarter San Francisco, United States
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Profusa, Inc.
Operational Areas
Healthcare → Health Technology & Digital Health
Technology → Extended, Virtual & Augmented Reality
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $64.92 M (USD)

    in 19 rounds

  • Latest Funding Round
    $45 M (USD), Series C

    Aug 14, 2018

  • Investors
    Nasdaq

    & 10 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Profusa

Profusa offers a comprehensive portfolio of products and services, including Lumee Oxygen Platform and Glucose Biosensors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Continuous tissue oxygen monitoring is enabled by this platform.

Glucose levels are monitored continuously with innovative biosensor technology.

Funding Insights of Profusa

Profusa has successfully raised a total of $64.92M across 19 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 19
  • Last Round Series C — $45.0M
  • First Round

    (10 Mar 2011)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2018 Amount Series C - Profusa Valuation Tasly , Maxim Ventures
Apr, 2017 Amount Grant - Profusa Valuation

investors

HHS
Sep, 2016 Amount Grant - Profusa Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Profusa

Profusa has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Nasdaq, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech & Life Science focused early & growth stage VC firm investing in the US & China
Founded Year Domain Location
VC firm investing in geographies such as South Korea
Founded Year Domain Location
Early-stage US companies are invested in by Asset Management Ventures.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Profusa

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Profusa

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Profusa Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Profusa

Profusa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Theranica, Mainstay Medical, Sooma Oy, SPR Therapeutics and ZetrOZ, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutic devices for pain management are developed and manufactured.
domain founded_year HQ Location
Provider of rehabilitation solutions for patients and doctors
domain founded_year HQ Location
Non-invasive neuromodulation therapies
domain founded_year HQ Location
Pioneers non-invasive devices for chronic pain relief through medical innovation.
domain founded_year HQ Location
Wearable bioelectronic devices for acoustic medicine treatments are developed.
domain founded_year HQ Location
Wearable therapeutic fabrics for pain management are offered by Nufabrx.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Profusa

When was Profusa founded?

Profusa was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is Profusa located?

Profusa is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Is Profusa a funded company?

Profusa is a funded company, having raised a total of $64.92M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.22M, raised on Mar 10, 2011.

What does Profusa do?

Profusa, Inc. is engaged in the development of innovative tissue-integrating biosensors designed for continuous monitoring of body chemistries. The companys flagship product, the Lumee Oxygen Platform, is utilized for real-time tissue oxygen monitoring and has received CE Mark approval in the European Union. Additionally, glucose biosensors are being pioneered to expand monitoring capabilities. Solutions are targeted at healthcare applications, particularly in critical limb ischemia and influenza detection, with potential for telehealth and remote patient monitoring. Research and partnerships, including DARPA-backed studies, are leveraged to enhance early disease detection and improve clinical management in the medical sector.

Who are the top competitors of Profusa?

Profusa's top competitors include Theranica, Mainstay Medical and Nufabrx.

What products or services does Profusa offer?

Profusa offers Lumee Oxygen Platform and Glucose Biosensors.

Who are Profusa's investors?

Profusa has 11 investors. Key investors include Nasdaq, NIH, HHS, Atinum Investment, and SBIR.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available